Tau-aggregation-IN-5 

Tau-aggregation-IN-5 is a Tau-aggregation inhibitor (EC₅₀ = 0.31 μM). Tau-aggregation-IN-5 targets P4HB covalently and activates mild ER stress. Tau-aggregation-IN-4 can be used for the study of neurodegenerative disorders such as Alzheimer’s and Pick’s diseases^[1].

Tau-aggregation-IN-5 (Compound 2a) (0.008-10 μM,) dose-dependently clears tau accumulation in human induced pluripotent stem cell (hiPSC)-derived neurons, with an EC₅₀ of 190 nM and a maximum clearance rate exceeding 90%^[1].
Tau-aggregation-IN-5 (3 μM, 24 h) does not affect the level of non-aggregated tau protein in SH-SY5Y cells^[1].
Tau-aggregation-IN-5 (10 μM, 6 hours) results in significant changes in the expression of 590 genes in 22,537 transcripts in SH-SY5Y cells, including ERO1B, HSPA5, and HERPUD1^[1].
Tau-aggregation-IN-5 (10 μM, 2-6 h) significantly upregulates the ERAD-associated protein HERPUD1 in SH-SY5Y cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

251.28

C₁₅H₁₃N₃O

1283397-08-9

O=C(C1=CNC2=C1C=CC(N)=C2)NC3=CC=CC=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Conway LP, et al. Discovery of a tau-aggregate clearing compound that covalently targets P4HB. Cell Chem Biol. 2025 Oct 16;32(10):1235-1248.e34.  [Content Brief]